Gulfo Adele M. 4
4 · Tyra Biosciences, Inc. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Tyra Biosciences Director Gulfo Adele Receives Option Award (13,160)
What Happened
Gulfo Adele, a director of Tyra Biosciences (TYRA), was granted an option award covering 13,160 shares on May 28, 2026. The transaction is reported as an award/acquisition with a reported price of $0.00 (derivative grant), meaning this was a stock-option or similar equity award, not an open-market purchase or sale.
Key Details
- Transaction date: May 28, 2026; Form filed June 1, 2026.
- Transaction type: Award/Grant (derivative) of 13,160 shares; reported acquisition price $0.00.
- Vesting: 1/12th of the total option vests monthly beginning May 28, 2026. If the next annual stockholder meeting occurs before the one-year anniversary, any remaining unvested portion will vest on that meeting date, subject to continued service. (From filing footnote.)
- Shares owned after transaction: Not specified in this filing.
- Filing timeliness: Form filed four days after the grant; filing does not indicate a late-report flag in the provided data.
Context
This was an equity compensation grant under Tyra’s Non-Employee Director Compensation Program for a board member. Such grants are routine for directors and vest over time as described; they do not represent an immediate cash purchase or sale and should be viewed as compensation rather than a direct market sentiment signal.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-05-28+13,160→ 13,160 totalExercise: $32.68Exp: 2036-05-27→ Common Stock (13,160 underlying)
Footnotes (1)
- [F1]The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.